Progress in the surgical management of vaginal rhabdomyosarcoma

A 25- year review from the Intergroup Rhabdomyosarcoma Study Group

R. J. Andrassy, E. S. Wiener, R. B. Raney, D. M. Hays, Carola A.S. Arndt, T. E. Lobe, W. Lawrence, J. R. Anderson, S. J. Qualman, W. M. Crist

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Background/Purpose: During its 25 years of experience, the Intergroup Rhabdomyosarcoma Study Group (IRSG) has completed four sequential prospective clinical trials to improve survival and decrease morbidity rates in childhood rhabdomyosarcoma (RMS). Surgical management of vaginal RMS has changed dramatically. Methods: The records of 72 patients with localized vaginal RMS were reviewed to assess surgical therapy, chemotherapy, and radiotherapy and their relation to outcome. Results: Each successive IRSG trial resulted in decreased need for surgical resection (IRS-I, 100%; IRS-II, 70%; IRS-III, 30%; IRS-IV, 13%) and excellent disease-free survival using increasingly effective multiagent chemotherapy. Conclusions: Primary chemotherapy after initial biopsy provides excellent tumor control. Local resection may be appropriate, but removal of organs (ie, complete vaginectomy/hysterectomy) has no role except in persistent or recurrent disease. Mature, residual rhabdomyoblasts may be evidence of a chemotherapy response, and further surveillance and biopsy without surgical resection is adequate treatment.

Original languageEnglish (US)
Pages (from-to)731-735
Number of pages5
JournalJournal of Pediatric Surgery
Volume34
Issue number5
DOIs
StatePublished - May 1999

Fingerprint

Rhabdomyosarcoma
Drug Therapy
Biopsy
Hysterectomy
Disease-Free Survival
Radiotherapy
Clinical Trials
Morbidity
Survival
Therapeutics
Neoplasms

Keywords

  • Rhabdomyosarcoma
  • Vaginal

ASJC Scopus subject areas

  • Surgery

Cite this

Progress in the surgical management of vaginal rhabdomyosarcoma : A 25- year review from the Intergroup Rhabdomyosarcoma Study Group. / Andrassy, R. J.; Wiener, E. S.; Raney, R. B.; Hays, D. M.; Arndt, Carola A.S.; Lobe, T. E.; Lawrence, W.; Anderson, J. R.; Qualman, S. J.; Crist, W. M.

In: Journal of Pediatric Surgery, Vol. 34, No. 5, 05.1999, p. 731-735.

Research output: Contribution to journalArticle

Andrassy, RJ, Wiener, ES, Raney, RB, Hays, DM, Arndt, CAS, Lobe, TE, Lawrence, W, Anderson, JR, Qualman, SJ & Crist, WM 1999, 'Progress in the surgical management of vaginal rhabdomyosarcoma: A 25- year review from the Intergroup Rhabdomyosarcoma Study Group', Journal of Pediatric Surgery, vol. 34, no. 5, pp. 731-735. https://doi.org/10.1016/S0022-3468(99)90365-2
Andrassy, R. J. ; Wiener, E. S. ; Raney, R. B. ; Hays, D. M. ; Arndt, Carola A.S. ; Lobe, T. E. ; Lawrence, W. ; Anderson, J. R. ; Qualman, S. J. ; Crist, W. M. / Progress in the surgical management of vaginal rhabdomyosarcoma : A 25- year review from the Intergroup Rhabdomyosarcoma Study Group. In: Journal of Pediatric Surgery. 1999 ; Vol. 34, No. 5. pp. 731-735.
@article{dd758e6fbbd041fdada31b2cf4d812cf,
title = "Progress in the surgical management of vaginal rhabdomyosarcoma: A 25- year review from the Intergroup Rhabdomyosarcoma Study Group",
abstract = "Background/Purpose: During its 25 years of experience, the Intergroup Rhabdomyosarcoma Study Group (IRSG) has completed four sequential prospective clinical trials to improve survival and decrease morbidity rates in childhood rhabdomyosarcoma (RMS). Surgical management of vaginal RMS has changed dramatically. Methods: The records of 72 patients with localized vaginal RMS were reviewed to assess surgical therapy, chemotherapy, and radiotherapy and their relation to outcome. Results: Each successive IRSG trial resulted in decreased need for surgical resection (IRS-I, 100{\%}; IRS-II, 70{\%}; IRS-III, 30{\%}; IRS-IV, 13{\%}) and excellent disease-free survival using increasingly effective multiagent chemotherapy. Conclusions: Primary chemotherapy after initial biopsy provides excellent tumor control. Local resection may be appropriate, but removal of organs (ie, complete vaginectomy/hysterectomy) has no role except in persistent or recurrent disease. Mature, residual rhabdomyoblasts may be evidence of a chemotherapy response, and further surveillance and biopsy without surgical resection is adequate treatment.",
keywords = "Rhabdomyosarcoma, Vaginal",
author = "Andrassy, {R. J.} and Wiener, {E. S.} and Raney, {R. B.} and Hays, {D. M.} and Arndt, {Carola A.S.} and Lobe, {T. E.} and W. Lawrence and Anderson, {J. R.} and Qualman, {S. J.} and Crist, {W. M.}",
year = "1999",
month = "5",
doi = "10.1016/S0022-3468(99)90365-2",
language = "English (US)",
volume = "34",
pages = "731--735",
journal = "Journal of Pediatric Surgery",
issn = "0022-3468",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Progress in the surgical management of vaginal rhabdomyosarcoma

T2 - A 25- year review from the Intergroup Rhabdomyosarcoma Study Group

AU - Andrassy, R. J.

AU - Wiener, E. S.

AU - Raney, R. B.

AU - Hays, D. M.

AU - Arndt, Carola A.S.

AU - Lobe, T. E.

AU - Lawrence, W.

AU - Anderson, J. R.

AU - Qualman, S. J.

AU - Crist, W. M.

PY - 1999/5

Y1 - 1999/5

N2 - Background/Purpose: During its 25 years of experience, the Intergroup Rhabdomyosarcoma Study Group (IRSG) has completed four sequential prospective clinical trials to improve survival and decrease morbidity rates in childhood rhabdomyosarcoma (RMS). Surgical management of vaginal RMS has changed dramatically. Methods: The records of 72 patients with localized vaginal RMS were reviewed to assess surgical therapy, chemotherapy, and radiotherapy and their relation to outcome. Results: Each successive IRSG trial resulted in decreased need for surgical resection (IRS-I, 100%; IRS-II, 70%; IRS-III, 30%; IRS-IV, 13%) and excellent disease-free survival using increasingly effective multiagent chemotherapy. Conclusions: Primary chemotherapy after initial biopsy provides excellent tumor control. Local resection may be appropriate, but removal of organs (ie, complete vaginectomy/hysterectomy) has no role except in persistent or recurrent disease. Mature, residual rhabdomyoblasts may be evidence of a chemotherapy response, and further surveillance and biopsy without surgical resection is adequate treatment.

AB - Background/Purpose: During its 25 years of experience, the Intergroup Rhabdomyosarcoma Study Group (IRSG) has completed four sequential prospective clinical trials to improve survival and decrease morbidity rates in childhood rhabdomyosarcoma (RMS). Surgical management of vaginal RMS has changed dramatically. Methods: The records of 72 patients with localized vaginal RMS were reviewed to assess surgical therapy, chemotherapy, and radiotherapy and their relation to outcome. Results: Each successive IRSG trial resulted in decreased need for surgical resection (IRS-I, 100%; IRS-II, 70%; IRS-III, 30%; IRS-IV, 13%) and excellent disease-free survival using increasingly effective multiagent chemotherapy. Conclusions: Primary chemotherapy after initial biopsy provides excellent tumor control. Local resection may be appropriate, but removal of organs (ie, complete vaginectomy/hysterectomy) has no role except in persistent or recurrent disease. Mature, residual rhabdomyoblasts may be evidence of a chemotherapy response, and further surveillance and biopsy without surgical resection is adequate treatment.

KW - Rhabdomyosarcoma

KW - Vaginal

UR - http://www.scopus.com/inward/record.url?scp=13044270977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13044270977&partnerID=8YFLogxK

U2 - 10.1016/S0022-3468(99)90365-2

DO - 10.1016/S0022-3468(99)90365-2

M3 - Article

VL - 34

SP - 731

EP - 735

JO - Journal of Pediatric Surgery

JF - Journal of Pediatric Surgery

SN - 0022-3468

IS - 5

ER -